In vivo effects of abused 'bath salt' constituent 3,4- methylenedioxypyrovalerone (MDPV) in mice: Drug discrimination, thermoregulation, and locomotor activity

Neuropsychopharmacology

Volumn 38, Issue 4, 2013, Pages 563-573

  Fantegrossi, William E ^a   Gannon, Brenda M ^a   Zimmerman, Sarah M ^a   Rice, Kenner C ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

behavior; cathinone; designer drug; locomotor activity; thermoregulation

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 3,4 METHYLENEDIOXYPYROVALERONE; METHAMPHETAMINE; PYROVALERONE; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOMUTILATION; BEHAVIOR; CONTROLLED STUDY; DRUG DISCRIMINATION; DRUG EFFECT; DRUG MONITORING; ENVIRONMENTAL TEMPERATURE; HYPERTHERMIA; IN VIVO STUDY; LOCOMOTION; MALE; MOTOR ACTIVITY; MOUSE; NERVE STIMULATION; NONHUMAN; PRIORITY JOURNAL; STEREOTYPY; STIMULUS RESPONSE; TELEMETRY; THERMOREGULATION;

ANIMALS; BENZODIOXOLES; BODY TEMPERATURE REGULATION; CONDITIONING, OPERANT; DESIGNER DRUGS; DISCRIMINATION (PSYCHOLOGY); MALE; MICE; MOTOR ACTIVITY; PYRROLIDINES;

EID: 84873724416     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2012.233     Document Type: Article

References (57)

1. American Association of Poison Control Centers (2012): Bath Salts Data, Updated September 10, 2012. Accessed 13 September 2012 at aapcc.org/dnn/Portals/ 0/Bath%20Salts%20Data%20for%20-Website%208.2012%282%29.pdf.
2. Baumann MH, Ayestas MA Jr, Partilla JS, Sink JR, Shulgin AT, Daley PF et al (2012a). The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology 37: 1192-1203.
3. Baumann MH, Partilla JS, Lehner KR, Thorndike EB, Hoffman AF, Holy M et al (2012b). Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products. Neuropsychopharmacology doi: 10.1038/npp.2012.204.
4. Borek HA, Holstege CP (2012). Hyperthermia and multiorgan failure after abuse of 'bath salts' containing 3,4-methylenedioxypyrovalerone. Ann Emerg Med 60: 103-105.
5. Chu T, Kumagai Y, DiStefano EW, Cho AK (1996). Disposition of methylenedioxymethamphetamine and three metabolites in the brains of different rat strains and their possible roles in acute serotonin depletion. Biochem Pharmacol 51: 789-796.
6. Dafters RI (1994). Effect of ambient temperature on hyperthermia and hyperkinesis induced by 3,4-methylenedioxymethamphetamine (MDMA or 'ecstasy') in rats. Psychopharmacology (Berl) 114: 505-508.
7. Dal Cason TA, Young R, Glennon RA (1997). Cathinone: an investigation of several N-alkyl and methylenedioxy-substituted analogs. Pharmacol Biochem Behav 58: 1109-1116.
8. de la Torre R, Farré M, Ortuño J, Mas M, Brenneisen R, Roset PN et al (2000). Non-linear pharmacokinetics of MDMA ('ecstasy') in humans. Br J Clin Pharmacol 49: 104-109.
9. Devine DP (2012). The pemoline model of self-injurious behaviour. Methods Mol Biol 829: 155-163.
10. Fantegrossi WE, Ciullo JR, Wakabayashi KT, De La Garza R II, Traynor JR, Woods JH (2008). A comparison of the physiological, behavioral, neurochemical and microglial effects of methamphetamine and 3,4-methylenedioxymethamphetamine in the mouse. Neuroscience 151: 533-543.
11. Fantegrossi WE, Murai N, Mathúna BO, Pizarro N, de la Torre R (2009). Discriminative stimulus effects of 3,4-methylenedioxymethamphetamine and its enantiomers in mice: pharmacokinetic considerations. J Pharmacol Exp Ther 329: 1006-1015.
12. Fauquet JP, Morel E, Demarty C, Rapin JR (1976). Role of central catecholamines in the psychostimulant activity of pyrovalerone. Arch Int Pharmacodyn Ther 224: 325-337.
13. Fuwa T, Fukumori N, Tanaka T, Kubo Y, Ogata A, Uehara S et al (2007). Microdialysis study of drug effects on central nervous system-changes of dopamine levels in mice striatum after oral administration of methylenedioxypyrovalerone. Ann Rep Tokyo Metr Inst PH 58: 287-292.
14. Goldberg J, Gardos G, Cole JO (1973). A controlled evaluation of pyrovalerone in chronically fatigued volunteers. Int Pharmacopsychiatry 8: 60-69.
15. Granado N, Ares-Santos S, Oliva I, O'Shea E, Martin ED, Colado MI et al 2011). Dopamine D2-receptor knockout mice are protected against dopaminergic neurotoxicity induced by methamphetamine or MDMA. Neurobiol Dis 42: 391-403.
16. Heron C, Costentin J, Bonnet JJ (1994). Evidence that pure uptake inhibitors including cocaine interact slowly with the dopamine neuronal carrier. Eur J Pharmacol 264: 391-398.
17. Holliday AR, Morris RB, Sharpley RP (1964). Compound 84/F 1983 compared with D-amphetamine and placebo in regard to effects on human performance. Psychopharmacologia 6: 192-200.
18. Huang PK, Aarde SM, Angrish D, Houseknecht KL, Dickerson TJ, Taffe MA (2012). Contrasting effects of d-methamphetamine, 3,4- methylenedioxymethamphetamine, 3,4-methylenedioxypyrovalerone, and 4-methylmethcathinone on wheel activity in rats. Drug Alcohol Depend 126: 168-175.
19. Itzhak Y, Achat-Mendes C (2004). Methamphetamine and MDMA (ecstasy) neurotoxicity: 'of mice and men'. IUBMB Life 56: 249-255.
20. Itzhak Y, Anderson KL, Ali SF (2004). Differential response of nNOS knockout mice to MDMA ('ecstasy')-and methamphetamine-induced psychomotor sensitization and neurotoxicity. Ann NY Acad Sci 1025: 119-128.
21. Jinnah HA, Yitta S, Drew T, Kim BS, Visser JE, Rothstein JD (1999). Calcium channel activation and self-biting in mice. Proc Natl Acad Sci USA 96: 15228-15232.
22. Johanson CE, Kilbey M, Gatchalian K, Tancer M (2006). Discriminative stimulus effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans trained to discriminate among d-amphetamine, meta-chlorophenylpiperazine and placebo. Drug Alcohol Depend 81: 27-36.
23. Kasim S, Egami K, Jinnah HA (2002). Self-biting induced by activation of L-type calcium channels in mice: serotonergic influences. Dev Neurosci 24: 322-327.
24. Kita T, Matsunari Y, Saraya T, Shimada K, O'Hara K, Kubo K et al (2000). Methamphetamine-induced striatal dopamine release, behavior changes and neurotoxicity in BALB/c mice. Int J Dev Neurosci 18: 521-530.
25. Kyle PB, Iverson RB, Gajagowni RG, Spencer L 2011). Illicit bath salts: not for bathing. J Miss State Med Assoc 52: 375-377.
26. Leonhart MM 2011). Schedules of controlled substances: temporary placement of three synthetic cathinones into schedule I. Fed Reg 76: 65371-65375.
27. Leslie JC, Shaw D, Gregg G, McCormick N, Reynolds DS, Dawson GR (2005). Effects of reinforcement schedule on facilitation of operant extinction by chlordiazepoxide. J Exp Anal Behav 84: 327-338.
28. Malberg JE, Seiden LS (1998). Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat. J Neurosci 18: 5086-5094.
29. Mann H, Ladenheim B, Hirata H, Moran TH, Cadet JL (1997). Differential toxic effects of methamphetamine (METH) and methylenedioxymethamphetamine (MDMA) in multidrug-resistant (mdr1a) knockout mice. Brain Res 769: 340-346.
30. Mardikar BR, Srinivasan S, Balwani JH (1969). On the phenomenon of caffeine induced automutilation. Indian J Physiol Pharmacol 13: 261-263.
31. Mechan A, Yuan J, Hatzidimitriou G, Irvine RJ, McCann UD, Ricaurte GA (2006). Pharmacokinetic profile of single and repeated oral doses of MDMA in squirrel monkeys: relationship to lasting effects on brain serotonin neurons. Neuropsychopharmacology 31: 339-350.
32. Meltzer PC, Butler D, Deschamps JR, Madras BK (2006). 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem 49: 1420-1432.
33. Mueller M, Peters FT, Maurer HH, McCann UD, Ricaurte GA (2008). Nonlinear pharmacokinetics of (\+/-)3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy') and its major metabolites in squirrel monkeys at plasma concentrations of MDMA that develop after typical psychoactive doses. J Pharmacol Exp Ther 327: 38-44.
34. Murnane KS, Murai N, Howell LL, Fantegrossi WE (2009). Discriminative stimulus effects of psychostimulants and hallucinogens in S(\+)-3,4- methylenedioxymethamphetamine (MDMA) and R(-)-MDMA trained mice. J Pharmacol Exp Ther 331: 717-723.
35. Murnane KS, Perrine SA, Finton BJ, Galloway MP, Howell LL, Fantegrossi WE (2012). Effect of exposure to amphetamine derivatives on passive avoidance performance and the central levels of monoamines and their metabolites in mice: correlations between behavior and neurochemistry. Psychopharmacology 220: 495-508.
36. Murray BL, Murphy CM, Beuhler MC (2012). Death following recreational use of designer drug 'bath salts' containing 3,4-Methylenedioxypyrovalerone (MDPV). J Med Toxicol 8: 69-75.
37. Nevin JA, Mandell C, Atak JR (1983). The analysis of behavioral momentum. J Exp Anal Behav 39: 49-59.
38. O'Callaghan JP, Miller DB (1994). Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J Pharmacol Exp Ther 270: 741-751.
39. O'Shea E, Escobedo I, Orio L, Sanchez V, Navarro M, Green AR et al (2005). Elevation of ambient room temperature has differential effects on MDMA-induced 5-HT and dopamine release in striatum and nucleus accumbens of rats. Neuropsychopharmacology 30: 1312-1323.
40. Panas HN, Lynch LJ, Vallender EJ, Xie Z, Chen GL, Lynn SK et al (2010). Normal thermoregulatory responses to 3-iodothyronamine, trace amines and amphetamine-like psychostimulants in trace amine associated receptor 1 knockout mice. J Neurosci Res 88: 1962-1969.
41. Pinkston JW, Ginsburg BC, Lamb RJ (2009). Examination of reinforcement magnitude on the pharmacological disruption of fixed-ratio performance. Exp Clin Psychopharmacol 17: 237-246.
42. Poling A, Byrne T, Christian L, Lesage MG (2000). Effects of cocaine and morphine under mixed-ratio schedules of food delivery: support for a behavioral momentum analysis. Pharmacol Biochem Behav 66: 313-321.
43. Razzak A, Fujiwara M, Ueki S (1975). Automutilation induced by clonidine in mice. Eur J Pharmacol 30: 356-359.
44. Rodvelt KR, Lever SZ, Lever JR, Blount LR, Fan KH, Miller DK 2011). SA 4503 attenuates cocaine-induced hyperactivity and enhances methamphetamine substitution for a cocaine discriminative stimulus. Pharmacol Biochem Behav 97: 676-682.
45. Ross EA, Watson M, Goldberger B 2011). "Bath salts" intoxication. N Engl J Med 365: 967-968.
46. Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI et al (2001). Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39: 32-41.
47. Rudnick G, Wall S (1992). The molecular mechanism of (3,4-methylenedioxy- methamphetamine (MDMA)): serotonin transporters are targets for MDMA-induced serotonin release. Proc Nat Acad Sci USA 89: 1817-1821.
48. Shishido T, Watanabe Y, Kato K, Horikoshi R, Niwa SI (2000). Effects of dopamine, NMDA, opiate, and serotonin-related agents on acute methamphetamine-induced self-injurious behavior in mice. Pharmacol Biochem Behav 66: 579-583.
49. Simmler LD, Buser TA, Donzelli M, Schramm Y, Dieu LH, Huwyler J et al (2012). Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol doi: 10.1111/j.1476-5381.2012.02145.x.
50. Spiller HA, Ryan ML, Weston RG, Jansen J 2011). Clinical experience with and analytical confirmation of 'bath salts' and "legal highs" (synthetic cathinones) in the United States. Clin Toxicol 49: 499-505.
51. Tidjane Corera A, Do-Rego JC, Costentin J, Bonnet JJ (2001). Differential sensitivity to NaCl for inhibitors and substrates that recognize mutually exclusive binding sites on the neuronal transporter of dopamine in rat striatal membranes. Neurosci Res 39: 319-325.
52. US Drug Enforcement Administration, Office of Diversion Control 2011): National Forensic Laboratory Information System Special Report: Synthetic Cannabinoids and Synthetic Cathinones Reported in NFLIS, 2009-2010. Springfield, VA: U.S. Drug Enforcement Administration. Accessed 13 September 2012 at deadiversion.usdoj.gov/nflis/2010rx-synth.pdf.
53. Varner KJ, Daigle K, Weed PF, Lewis PB, Mahne SE, Sankaranarayanan A et al (2012). Comparison of the behavioral and cardiovascular effects of mephedrone with other drugs of abuse in rats. Psychopharmacology (Berl); e-pub ahead of print 20 November 2012.
54. Vaugeois JM, Bonnet JJ, Duterte-Boucher D, Costentin J (1993). In vivo occupancy of the striatal dopamine uptake complex by various inhibitors does not predict their effects on locomotion. Eur J Pharmacol 230: 195-201.
55. Wagner GC, Avena N, Kita T, Nakashima T, Fisher H, Halladay AK (2004). Risperidone reduction of amphetamineinduced self-injurious behavior in mice. Neuropharmacology 46: 700-708.
56. Watterson LR, Kufahl PR, Nemirovsky NE, Sewalia K, Grabenauer M, Thomas BF et al (2012). Potent rewarding and reinforcing effects of the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV). Addict Biol doi: 10.1111/j.1369-1600. 2012.00474.x.
57. Wright MJ Jr, Angrish D, Aarde SM, Barlow DJ, Buczynski MW, Creehan KM et al (2012). Effect of ambient temperature on the thermoregulatory and locomotor stimulant effects of 4-methylmethcathinone in wistar and sprague-dawley rats. PLoS One 7: e44652.